NASDAQ : GOSS
Gossamer Bio, Inc. — Key statistics
Healthcare · Biotechnology · United States
Last price 10.38 USD (Oct 30, 2026, 4:00 PM EDT) · Market cap 63.49M
Overview · Financial statements · Key statistics · Dividends · Company profile · Price history · Reports
Key statistics
Valuation
| Measure | Value |
|---|
| Market Cap | 58.11M |
| Enterprise Value | 41.15M |
Dates
| Measure | Value |
|---|
| Earnings Date | Nov 13, 2026 |
| Ex-Dividend Date | n/a |
Shares
| Measure | Value |
|---|
| Current Share Class | 6.12M |
| Shares Outstanding | 6.12M |
| Shares Change (YoY) | +11.86% |
| Shares Change (QoQ) | +40.42% |
| Owned by Insiders (%) | 1.54% |
| Owned by Institutions (%) | 76.28% |
| Float | 4.20M |
Ratios
| Measure | Value |
|---|
| PE Ratio | n/a |
| Forward PE | n/a |
| PS Ratio | 1.19 |
| Forward PS | 3.77 |
| PB Ratio | n/a |
| P/TBV Ratio | n/a |
| P/FCF Ratio | n/a |
| P/OCF Ratio | n/a |
| PEG Ratio | n/a |
Evratios
| Measure | Value |
|---|
| EV / Earnings | n/a |
| EV / Sales | 0.87 |
| EV / EBITDA | n/a |
| EV / EBIT | n/a |
| EV / FCF | n/a |
Financialposition
| Measure | Value |
|---|
| Current Ratio | 0.53 |
| Quick Ratio | 0.46 |
| Debt / Equity | n/a |
| Debt / EBITDA | n/a |
| Debt / FCF | n/a |
| Interest Coverage | -14.47 |
Financialefficiency
| Measure | Value |
|---|
| Return on Equity (ROE) | n/a |
| Return on Assets (ROA) | -62.39% |
| Return on Invested Capital (ROIC) | -192.94% |
| Return on Capital Employed (ROCE) | 260.39% |
| Weighted Average Cost of Capital (WACC) | 18.61% |
| Revenue Per Employee | $328,926 |
| Profits Per Employee | -$772,981 |
| Employee Count | 162 |
| Asset Turnover | 0.34 |
| Inventory Turnover | n/a |
Taxes
| Measure | Value |
|---|
| Income Tax | -88,000 |
| Effective Tax Rate | n/a |
Stockprice
| Measure | Value |
|---|
| Beta (5Y) | 2.27 |
| 52-Week Price Change | -95.13% |
| 50-Day Moving Average | 11.21 |
| 200-Day Moving Average | 40.24 |
| Relative Strength Index (RSI) | 44.68 |
| Average Volume (20 Days) | 209,645 |
Shortselling
| Measure | Value |
|---|
| Short Interest | 1.44M |
| Short Previous Month | 1.24M |
| Short % of Shares Out | 23.48% |
| Short % of Float | 34.19% |
| Short Ratio (days to cover) | 4.53 |
Incomestatement
| Measure | Value |
|---|
| Revenue | 53.29M |
| Gross Profit | 53.29M |
| Operating Income | -158.62M |
| Pretax Income | -125.31M |
| Net Income | -125.22M |
| EBITDA | -158.60M |
| EBIT | -158.62M |
| Loss Per Share | -$51.97 |
Balancesheet
| Measure | Value |
|---|
| Cash & Cash Equivalents | 57.03M |
| Total Debt | 40.07M |
| Net Cash | 16.96M |
| Net Cash Per Share | $2.77 |
| Equity (Book Value) | -94.03M |
| Book Value Per Share | -15.39 |
| Working Capital | -65.06M |
Cashflow
| Measure | Value |
|---|
| Operating Cash Flow | -162.63M |
| Capital Expenditures | n/a |
| Depreciation & Amortization | 21,000 |
| Net Borrowing | n/a |
| Free Cash Flow | -162.63M |
| FCF Per Share | -$26.59 |
Margins
| Measure | Value |
|---|
| Gross Margin | 100.00% |
| Operating Margin | -297.67% |
| Pretax Margin | -235.17% |
| Profit Margin | -235.00% |
| EBITDA Margin | -297.63% |
| EBIT Margin | -297.67% |
| FCF Margin | n/a |
Dividends
| Measure | Value |
|---|
| Dividend Per Share | n/a |
| Dividend Yield | n/a |
| Dividend Growth (YoY) | n/a |
| Years of Dividend Growth | n/a |
| Payout Ratio | n/a |
| FCF Payout Ratio | n/a |
| Buyback Yield | -11.86% |
| Shareholder Yield | n/a |
| Earnings Yield | -547.04% |
| FCF Yield | -256.15% |
Analystforecasts
| Measure | Value |
|---|
| Price Target | $95.40 |
| Price Target Difference | 904.21% |
| Analyst Consensus | Buy |
| Analyst Count | 8 |
| Revenue Growth Forecast (3Y) | 13.37% |
| EPS Growth Forecast (3Y) | n/a |
Stocksplits
| Measure | Value |
|---|
| Last Split Date | Sep 11, 2026 |
| Split Type | Reverse |
| Split Ratio | 1:80 |
Scores
| Measure | Value |
|---|
| Altman Z-Score | -32.47 |
| Piotroski F-Score | 1 |
Fairvalue
| Measure | Value |
|---|
| Lynch Fair Value | n/a |
| Lynch Upside | n/a |
| Graham Number | n/a |
| Graham Upside | n/a |